Literature DB >> 33001049

Comparison of high-flow oxygen treatment and standard oxygen treatment in patients with hypertensive pulmonary edema.

Kemal Şener1, Mustafa Çalış1, Zikret Köseoğlu1, Sezai Sarı1, Mustafa Polat1, Durdu Mehmet Üzücek1, Sadiye Yolcu1.   

Abstract

OBJECTIVE: The aim compares the blood gases, vital signs, mechanical ventilation requirement, and length of hospitalization in patients with hypertensive pulmonary edema treated with standard oxygen therapy (SOT) and high-flow oxygen therapy (HFOT).
METHODS: This prospective observational study was conducted in patients with tachypneic, hypoxemic, hypertensive pulmonary edema. The patients' 0th, 1st, and 2nd hour blood gas results; 0th, 1st, and 2nd hour vital signs; requirement of endotracheal intubation, length of hospitalization, and the prognosis were recorded on the study form.
RESULTS: A total of 112 patients were included in this study, of whom 50 underwent SOT and 62 received HFOT. The initial blood gas analysis revealed significantly lower levels of pH, PaO2, and SpO2 and significantly higher levels of PaCO2 in the HFOT group. Patients in the HFOT group had significantly higher respiratory rate and pulse rate and significantly lower SpO2 values. The recovery of vital signs was significantly better in the HFOT group (p<0.05). Similarly, follow-up results of arterial blood gas analysis were better in the HFOT group (p<0.05). Both length of stay in the emergency department (p<0.05) and length of intensive care unit hospitalization s significantly shorter in the HFOT group (p<0.05).
CONCLUSION: HFOT can be much more effective in patients with hypertensive pulmonary edema than SOT as it shortens the length of stay both in the emergency service and in the intensive care unit. HFOT also provides better results in terms of blood gas analysis, heart rate, and respiratory rate in the follow-up period.

Entities:  

Mesh:

Year:  2020        PMID: 33001049      PMCID: PMC7585958          DOI: 10.14744/AnatolJCardiol.2020.50680

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


Introduction

Heart failure (HF) is a worldwide important problem because of its high prevalence, being 0.3%–2% in the general population and reaching up to 3%–5% in people aged 65 years and 25% in those aged >75 years (1-3). The rates of mortality and morbidity are seriously high in patients with HF. The mortality rates for 10 and 15 years are approximately 40% and 56%, respectively. In cases of severe HF, the annual mortality rate is 40%–70% (4). Moreover, one-third of patients with HF aged >65 years return to the emergency department (ED) within 3 months and half of them return in 6 months (5, 6). Early recognition and treatment of decompensated HF (DHF) in the ED is important for preventing morbidity, prolonged stay in the ED room, prolonged hospitalization, and mortality. There are several treatment options such as mask oxygen treatment, standard nasal cannula oxygen treatment (SOT), noninvasive mechanical ventilation (NIMV), and invasive mechanical ventilation (IMV) for patients with DHF. SOT is advantageous because of its easy application; however, it cannot provide high flow and positive pressure. Higher than 6 L/min with SOT causes dryness in the respiratory tract. In addition, incompatibility of the patients to the NIMV technique and aspiration risk, limitation of talking, and prevention of feeding can be accepted as disadvantages of this method. Invasive procedures such as endotracheal intubation may cause other complications (7). Recently, high-flow oxygen therapy (HFOT), an NIMV method, has been widely used in critically ill patients. This treatment moistens and heats the combination of air and oxygen. It is administered with high flow via a nasal cannula. HFOT has superior properties such as providing a positive pressure and a constant FiO2, sweeping the anatomic dead space, providing high flow, and offering much more comfort to the patients. Thus, HFOT has become popular in critically ill patients. However, acute respiratory failure ratio is increasing each day, and this situation results in much more crowded EDs, empty bed problems in intensive care units (ICUs), and unfortunately prolonged stay in the ED. Because of these problems, the use of NIMV techniques, including HFOT, has become valuable (8). In the present study, our aim was to compare the blood gases, vital signs, mechanical ventilation requirement, length of stay in the ED, and length of hospitalization in patients with hypertensive pulmonary edema treated with SOT and HFOT.

Methods

This prospective observational study was performed in patients with hypertensive pulmonary edema aged >18 years between January 1, 2019 and October 31, 2019 after obtaining approval from the Ethics Committee (No: 2020-457). Patient consent form was signed by each patient. Patients were divided into two groups according to the treatment method. The first group was treated with HFOT and the second group was treated with SOT. We recorded the 0th, 1st, and 2nd hour blood gas parameters (pH, PaO2, PaCO2, SaO2, etc.); vital signs such as mean blood pressure (MBP), heart rate (HR), respiratory rate (RR), SpO2, and fever; requirement of intubation; hospitalization place (clinic/ICU); length of stay in the ED, length of hospitalization; and the outcome (discharged/dead) for the two groups. Our study groups also received standard pulmonary edema treatment in addition to SOT/HFOT. Patients were administered 0.5–1 mg/kg loop diuretic and 5–10 mg/min glyceryl trinitrate according to their clinical status. An additional dose was administered if required. Blood gas analyses of the patients were performed via a Radiometer ABL90 flex (Radiometer, Copenhagen, Denmark) device. Standard wall-fixed oxygen (1–6 lt/dk) was used for SOT and titrated via a flowmeter. For HFOT, Vapotherm, Precision Flow (Exeter, USA) device was used. To the HFOT group, 100% FiO2 and 40 L/min oxygen were administered. The flow value and the FiO2 level were rearranged according to the 1st hour blood gas results. We provided endotracheal intubation decision for the following: Persistent or worsening hypoxemia Worsening tachypnea Worsening PaCO2 despite optimal O2 treatment Weakness in respiratory muscles Loss of safety in airway Worsening mental status The primary outcome of this study was change in blood gas results in both the HFOT and SOT groups. The secondary outcomes were requirement of IMV, number of hospitalization days, and mortality. Patients who underwent other NIMV techniques, hemodynamically unstable patients, those diagnosed with acute coronary syndrome, those with a low Glasgow Coma Scale score (≤12), patients with rapid serial intubation, and nontolerable patients were excluded from the study (Fig. 1).
Figure 1

Exclusion flow chart of the patients

Exclusion flow chart of the patients

Statistical analyses

Statistical comparisons were performed using the statistical software package SPSS 23.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov test was used for normal distribution. Normally distributed variables were analyzed using the unpaired t-test. Non-normally distributed variables were evaluated using the Mann–Whitney U test. Categorical variables are expressed in frequencies and percentages. The chi-square test was used to compare categorical variables. Paired t-test was used for continuous variables. Differences between the initial (0th) and 2nd hour pH and lactate values were evaluated using paired samples t-test. Definitive statistics were expressed as mean±standard deviation (SD) and median (interquartile range, IQR). A p value <0.05 was considered as statistically significant.

Results

We included 112 patients with HF with a mean age of 71.85±10.02 years (range: 49–97 years). There were 57 (50.9%) male patients. Patients with more than two comorbid chronic diseases constituted 78.6% of the study population. In total, 91 patients (81.3%) had hypertension, 80 (71.4%) had coronary artery disease, and 54 (48.2%) had diabetes mellitus. HFOT was administered to 62 (55.4%) patients, and SOT was administered to 50 (44.6%) patients. In both groups, the initial 0th, 1st, and 2nd hour pH, PaO2, HCO3, SaO2, and base deficit levels were lower and PaCO2 and lactate levels were higher. Similarly, the 0th, 1st, and 2nd hour HR, MBP, and RR values were high and SpO2 levels were low in both groups (Table 1).
Table 1

Laboratory results of the HFOT and SOT groups

Treatment methodtP

HFOT (n=62) Mean±SDSOT (n=50) Mean±SD
pH
 0th hour7.23±0.087.30±0.09-4.143<0.001
 1st hour7.32±0.067.33±0.09-0.3770.707
 2nd hour7.36±0.047.37±0.07-0.2280.820
PO2 (mm Hg)
 0th hour58.19±6.0563.54±9.28-3.671<0.001
 1st hour163.62±75.8480.24±21.867.521<0.001
 2nd hour143.93±44.8993.70±32.756.616<0.001
PaCO2 (mm Hg)
 0th hour54.64±12.0148.14±13.322.7120.008
 1st hour45.48±9.8343.66±10.870.9310.354
 2nd hour42.32±8.1240.20±9.011.3080.194
HCO3 (mmol/L)
 0th hour20.60±3.8821.80±4.01- 1.6060.111
 1st hour22.58±3.5422.59±3.99-0.0150.988
 2nd hour23.61±3.1323.48±3.660.2000.842
SpO2 (%)
 0th hour81.67±5.6086.04±6.43-3.837<0.001
 1st hour97.31±2.8092.20±4.707.42<0.001
 2nd hour97.84±1.9595.10±2.546.453<0.001
Lactate (mmol/L)
 0th hour27.93±17.0522.16±18.941.6950.093
 1st hour16.80±10.8320.18±19.50-1.1590.249
 2nd hour12.87±7.4515.90±10.69-1.7620.081
Base deficit (mmol/L)
 0th hour-3.47±5.24-1.94±6.02-1.4440.152
 1st hour-1.59±4.90-1.60±5.630.0110.991
 2nd hour-0.52±4.35-0.54±5.060.0270.979

Values are presented as mean±SD and analyzed by independent samples t-test

HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy

Laboratory results of the HFOT and SOT groups Values are presented as mean±SD and analyzed by independent samples t-test HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy A total of 98 (88.5%) patients were hospitalized, including 58 (59.2%) patients in the ICU and 40 (40.8%) in the clinic. During hospitalization, 109 (97.3%) patients survived and 3 (2.7%) died. Endotracheal intubation was not required in 96.4% (n=108) of the patients. There were no significant differences between the two groups in terms of gender (p=0.492), comorbid diseases (p=0.099), and age (p=0.441). There were no differences between the groups in terms of their laboratory results as follows: pH 1st hour (p=0.707), 2nd hour (p=0.820); PaCO2 1st hour (p=0.354), 2nd hour (p=0.194); HCO3 0th hour (p=0.111), 1st hour (p=0.988), and 2nd hour (p=0.842); lactate 0th hour (p=0.093), 1st hour (p=0.249), and 2nd hour (p=0.081); base deficit level 0th hour (p=0.152), 1st hour (p=0.991), and 2nd hour (p=0.979) (Table 1). The 0th hour pH and PaO2 levels were significantly higher in the SOT group than the 0th pH and SPO2 levels in the HFOT group (Table 1, Fig. 2).
Figure 2

Blood gas analyses diagram of HFOT and SOT groups

Blood gas analyses diagram of HFOT and SOT groups The initial 0th hour HR was higher in the HFOT group (p=0.001) (Table 1). Regarding other vital signs, there were no significant differences between the groups in the following values: HR (/min) 1st hour (p=0.728), 2nd hour (p=0.370); systolic pressure (mm Hg) 0th hour (p=0.747), 1st hour (p=0.232), and 2nd hour (p=0.058); diastolic pressure (mm Hg) 0th hour (p=0.533), 1st hour (p=0.135), and 2nd hour (p=0.371); and MBP (mm Hg) 0th hour (p=0.766), 1st hour (p=0.107), and 2nd hour (p=0.106) (Table 2). The 0th hour RR was statistically higher in the HFOT group (p<0.001). The 1st and 2nd hour RR values were significantly higher in the SOT group (1st hour p=0.001, 2nd hour p<0.001). Finger SpO2 at the 0th hour was higher in the SOT group (p<0.001). This value was higher in the HFOT group at the 1st and 2nd hour (p<0.001) (Table 2).
Table 2

Vital signs at 0th, 1st, and 2nd hour of the groups

Treatment methodtP

HFOT (n=62) Mean±SDSOT (n=50) Mean±SD
Pulse (/min)
 0th hour115.04±20.88102.18±20.463.271<0.001
 1st hour94.62±15.9795.86±21.31-0.3490.728
 2nd hour87.91±15.2190.70±17.47-0.9000.370
Systolic T.A (mm Hg)
 0th hour182.90±23.35181.40±25.710.3240.747
 1st hour147.74±17.12152.20±22.15-1.2010.232
 2nd hour130.64±14.47137.0±20.52-1.9180.058
Diastolic T.A (mm Hg)
 0th hour101.61±11.76100.20±12.030.6250.533
 1st hour84.83±9.7087.80±11.11-1.5040.135
 2nd hour77.2±9.0878.80±8.95-0.8990.371
MBP (mm Hg)
 0th hour127.74±14.42126.92±14.620.2980.766
 1st hour105.59±10.97109.38±13.66-1.6260.107
 2nd hour94.64±9.2997.86±11.58-1.6290.106
Respiratory rate (/min)
 0th hour33.59±4.8228.24±5.265.604<0.001
 1st hour23.46±4.1126.58±5.37-3.471<0.001
 2nd hour20.17±2.7124.06±4.54-5.607<0.001
SpO2 (%)
 0th hour82.24±5.6286.58±5.70-4.034<0.001
 1st hour97.41±2.8392.72±4.516.715<0.001
 2nd hour98.64±1.6995.94±2.277.207<0.001

Values are presented as mean±SD and analyzed by independent samples t-test

HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy; MBP - mean blood pressure; T.A - tension arterial

Vital signs at 0th, 1st, and 2nd hour of the groups Values are presented as mean±SD and analyzed by independent samples t-test HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy; MBP - mean blood pressure; T.A - tension arterial There were no significant differences between the groups in the primary outcome (p=0.440), admission place (clinic/ICU) (p=0.492), mortality (p=0.419), and intubation requirement (p=0.233) (Table 3).
Table 3

Differences between groups according to admission, mortality, intubation status, and outcome

Treatment methodχ2P

HFOT n (%)SOT n (%)
Outcome
 Discharge (n=14)7 (11.3)7 (14.0)0.1860.440
 Stay in hospital (n=98)55 (88.7)43 (86.0)
Admission
 Intensive care unit (n=58)32 (58.2)26 (60.5)0.0520.492
 Service (n=40)23 (41.8)17 (39.5)
Mortality
 Died (n=3)1 (1.6)2 (4.0)0.6050.419
 Alive (n=109)61 (98.4)48 (96.0)
Intubation requirement
 + (n=108)61 (98.4)47 (94.0)1.5470.233
 − (n=4)1 (1.6)3 (6.0)

Values are presented as number % and analyzed by the Mann–Whitney U test.

n: median; HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy; IQR - interquartile range

Differences between groups according to admission, mortality, intubation status, and outcome Values are presented as number % and analyzed by the Mann–Whitney U test. n: median; HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy; IQR - interquartile range The duration of hospitalization in service was longer in the SOT group but not statistically significant (p=0.622). However, the length of ICU hospitalization was significantly higher in the SOT group (p=0.040, Table 4).
Table 4

Differences between groups according to hospitalization time and outcome

HFOT Mean±SDSOT Mean±SDU/tP
Number of days in intensive care unit (n=63)2.45±1.725.11±7.44U: 332.50.040
Number of days in clinic (n=61)4.55±4.545.11±4.02U: 401.00.622
Total hospitalization day (n=97)4.55±4.116.23±6.55t: -1.5380.127

Values are presented as mean±SD and analyzed by independent samples t-test

HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy

Differences between groups according to hospitalization time and outcome Values are presented as mean±SD and analyzed by independent samples t-test HFOT - high-flow oxygen therapy; SOT - standard oxygen therapy The mean ejection fraction values were 41.40%±9.32% (range: 20%–60%) in the HFOT group and 42.14%±10.34% (range: 20%–60%) in the SOT group, with no significant difference between the groups (p=0.693). The mean length of stay in the ED was longer in the SOT group [233±79.64 min (range: 120–520 min)] than in the HFOT group [178.79±67.70 min (range: 20–480 min)] (p<0.001). The 2nd hour pH level was higher than the 0th hour pH level in the HFOT groups (p<0.001). Similarly, the 2nd hour pH level was higher than the 0th hour pH level in the SOT group (p<0.001) (Table 5). The 0th hour lactate levels were higher than the 2nd hour lactate levels in both groups (HFOT group p<0.001, SOT group p=0.001) (Table 5).
Table 5

Differences between groups according to lactate levels

0th hour pH Mean±SD2nd hour pH Mean±SDP
HFOT7.23±0.087.36±0.04<0.001
Standard oxygen treatment7.30±0.097.37±0.07<0.001
0th hour lactate2nd hour lactateP
HFOT27.93±17.0512.87±7.45<0.001
Standard oxygen treatment22.16±18.9415.90±10.69<0.001

Values are presented as mean±SD and analyzed by independent samples t-test

HFOT - high-flow oxygen therapy

Differences between groups according to lactate levels Values are presented as mean±SD and analyzed by independent samples t-test HFOT - high-flow oxygen therapy

Discussion

Hypertensive pulmonary edema is one of the serious life-threatening emergency conditions. HFOT, a noninvasive method, has several advantages because of its positive pressure property in clinical use in these patients. The amount of oxygen administered may increase up to 100% and provides a constant FiO2 support and diminishes the dead space in lungs (9-11). To our knowledge, the use of HFOT in patients with hypertensive pulmonary edema has not been well defined in the literature. In the present study, we determined better blood gas results with HFOT in patients with hypertensive pulmonary edema. Recently, Carratala et al. (12) reported that HFOT may be effective in patients with cardiogenic pulmonary edema, but they administered HFOT to those patients who had still been hypoxemic through the 24-hour oxygen treatment. After HFOT, they performed blood gas analysis that revealed that hypoxemia, tachypnea, and dyspnea resolved with HFOT. In addition, they suggested that HFOT is a much more useful and comfortable method. Similar to our results, the PO2 and SpO2 levels were better after HFOT. An important aspect was that none of our patients were denied HFOT because of discomfort. In another study, 20 patients with acute respiratory distress admitted to the ICU received HFOT and SOT. Better results for PO2 and SpO2 were observed with HFOT than with SOT. HFOT resulted in decreased RR, lower mouth dryness, and much more comfort (13). Sztrymf et al. (14) reported similar results in 20 patients with pneumonia-induced acute respiratory distress. They observed better results in respiratory functions and oxygenation parameters with HFOT. We observed that HFOT decreased the HR much more effectively than SOT. Similar to our results, HR and RR were decreased significantly with HFOT compared with SOT in the study of Carratala et al. (12). The difference in HR at the beginning improved at the 1st and 2nd hour in our study. Other NIMV techniques, including continuous airway pressure (CPAP) and bilevel positive airway pressure (BPAP), are well-known methods for patients with hypoxemic. CPAP is the primary choice in hypoxemic respiratory failure, and BPAP is used for hypercarbic patients, but discomfort and compatibility of patients are the disadvantages. The mechanism is similar to that of HFOT in terms of a high positive pressure (15). HFOT is a new method for treating respiratory failure and not widely used in critically ill patients in the EDs. NIMV may decrease the venous return and it must be used much more carefully in preload dependent patients (16). With HFOT, the airway pressure increases by 1.16 cm H2O for each rise of 10 L/min flow. This pressure increases postexpiratory pulmonary volume, pressure in the alveoles, and decreases the RR (17). Mauri et al. (18) reported that HFOT diminished the respiratory load of patients by affecting the central nervous system. According to their data, high FiO2 provides better oxygenation and comfort because of moisturized air, optimal tidal volume because of positive pressure, and decrease in CO2 levels and hypoxemia resolves (18). According to the literature, HFOT is generally explored for patients with acute respiratory distress and supportive results have been suggested (19). In an animal model experiment comparing HFOT and CPAP, a significant decrement in CO2 levels with HFOT was observed, and HFOT was suggested as an alternative for CPAP (20). In a randomized controlled prospective study, Makdee et al. (21) enrolled 128 patients with pulmonary edema and compared HFOT and SOT for determining the number of patients in terms of RR. It was observed that HFOT decreased the RR much more effectively at the 60th min of treatment. That study also suggested no significant difference between the groups according to the length of stay in the ED, number of hospitalization days, requirement of endotracheal intubation, and mortality (21). In our study, we determined shortened ED stay and shorter hospitalization period in the HFOT group. In an ICU-based retrospective study, the clinicians compared early and late intubated patients after unsuccessful HFOT. They observed that late intubated patients had higher mortality rates, low success in extubation process, and difficulty in separating from the ventilator (22). Lactate and base deficit levels have not been well defined in HFOT. In our study, the 2nd hour lactate levels were significantly lower in the HFOT group. This finding reveals that effective tissue and cell oxygenation was provided by HFOT.

Conclusion

HFOT in patients with hypertensive pulmonary edema demonstrated better improvement in terms of pH, PaO2, SpO2, fingertip SpO2, PaCO2, HR, and RR. It also shortened the length of stay in the ED and ICU. HFOT can be suggested as an effective method for patients with hypertensive pulmonary edema compared with SOT. Owing to the lack of literature, there is a need for prospective, comprehensive studies to further evaluate the efficacy of HFOT in patients with hypertensive pulmonary edema.

Study limitations

The study was conducted based on data from a single center and the number of patients was limited. Another limitation is that the length of stay of the patients in the emergency clinic sometimes had to be extended based on the bed availability in the services. A final limitation is that the blood gas values of those patients who were brought to the emergency clinic by ambulances were influenced by the nasal oxygen treatment that they received on the way.
  22 in total

1.  Heart failure: a global disease requiring a global response.

Authors:  J E Sanderson; T-f Tse
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

Review 2.  Noninvasive Ventilation for the Emergency Physician.

Authors:  Michael G Allison; Michael E Winters
Journal:  Emerg Med Clin North Am       Date:  2016-02       Impact factor: 2.264

3.  Effect of Very-High-Flow Nasal Therapy on Airway Pressure and End-Expiratory Lung Impedance in Healthy Volunteers.

Authors:  Rachael L Parke; Andreas Bloch; Shay P McGuinness
Journal:  Respir Care       Date:  2015-09-01       Impact factor: 2.258

4.  Changes in arterial blood gases after use of high-flow nasal cannula therapy in the ED.

Authors:  Jin Hee Jeong; Dong Hoon Kim; Seong Chun Kim; Changwoo Kang; Soo Hoon Lee; Tae-Sin Kang; Sang Bong Lee; Sang Min Jung; Dong Seob Kim
Journal:  Am J Emerg Med       Date:  2015-07-30       Impact factor: 2.469

5.  High-Flow therapy via nasal cannula in acute heart failure.

Authors:  José Manuel Carratalá Perales; Pere Llorens; Benjamín Brouzet; Alejandro Ricardo Albert Jiménez; José María Fernández-Cañadas; José Carbajosa Dalmau; Elena Martínez Beloqui; Sergio Ramos Forner
Journal:  Rev Esp Cardiol       Date:  2011-04-16       Impact factor: 4.753

6.  High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model.

Authors:  Meg Frizzola; Thomas L Miller; Maria Elena Rodriguez; Yan Zhu; Jorge Rojas; Anne Hesek; Angela Stump; Thomas H Shaffer; Kevin Dysart
Journal:  Pediatr Pulmonol       Date:  2010-11-23

7.  High-flow oxygen therapy in acute respiratory failure.

Authors:  Oriol Roca; Jordi Riera; Ferran Torres; Joan R Masclans
Journal:  Respir Care       Date:  2010-04       Impact factor: 2.258

8.  Delivered oxygen concentrations using low-flow and high-flow nasal cannulas.

Authors:  Richard B Wettstein; David C Shelledy; Jay I Peters
Journal:  Respir Care       Date:  2005-05       Impact factor: 2.258

9.  Heart failure: how can we prevent the epidemic?

Authors:  Duncan J Campbell
Journal:  Med J Aust       Date:  2003-10-20       Impact factor: 7.738

10.  Effect of high-flow nasal cannula oxygen therapy vs conventional oxygen therapy on adult postcardiothoracic operation: A meta-analysis.

Authors:  Xiu Wu; Wei Cao; Bin Zhang; Shengyu Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more
  1 in total

Review 1.  Physiological Effects of High-Flow Nasal Cannula Therapy and Its Use in Acute Cardiogenic Pulmonary Edema.

Authors:  Prakash Adhikari; Sanket Bhattarai; Ashish Gupta; Eiman Ali; Moeez Ali; Mohamed Riad; Jihan A Mostafa
Journal:  Cureus       Date:  2021-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.